117 related articles for article (PubMed ID: 28527113)
1. Mutant p53 promotes cell spreading and migration via ARHGAP44.
Xu J; Jiao J; Xu W; Ji L; Jiang D; Xie S; Kubra S; Li X; Fu J; Xiao J; Zhang B
Sci China Life Sci; 2017 Sep; 60(9):1019-1029. PubMed ID: 28527113
[TBL] [Abstract][Full Text] [Related]
2. ARHGAP44-mediated regulation of the p53/C-myc/Cyclin D1 pathway in modulating the malignant biological behavior of osteosarcoma cells.
Li S; Xue J; Zhang H; Shang G
J Orthop Surg Res; 2023 Nov; 18(1):910. PubMed ID: 38031136
[TBL] [Abstract][Full Text] [Related]
3. p53 and its mutants in tumor cell migration and invasion.
Muller PA; Vousden KH; Norman JC
J Cell Biol; 2011 Jan; 192(2):209-18. PubMed ID: 21263025
[TBL] [Abstract][Full Text] [Related]
4. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
Barta JA; Pauley K; Kossenkov AV; McMahon SB
Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
[TBL] [Abstract][Full Text] [Related]
5. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.
Neilsen PM; Noll JE; Mattiske S; Bracken CP; Gregory PA; Schulz RB; Lim SP; Kumar R; Suetani RJ; Goodall GJ; Callen DF
Oncogene; 2013 Jun; 32(24):2992-3000. PubMed ID: 22797073
[TBL] [Abstract][Full Text] [Related]
7. MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop.
Luo P; Wang Q; Ye Y; Zhang J; Lu D; Cheng L; Zhou H; Xie M; Wang B
J Exp Clin Cancer Res; 2019 Feb; 38(1):74. PubMed ID: 30755230
[TBL] [Abstract][Full Text] [Related]
8. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
9. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor β (TGF-β) pathway.
Ji L; Xu J; Liu J; Amjad A; Zhang K; Liu Q; Zhou L; Xiao J; Li X
J Biol Chem; 2015 May; 290(18):11729-40. PubMed ID: 25767119
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 on the Path to Metastasis.
Tang Q; Su Z; Gu W; Rustgi AK
Trends Cancer; 2020 Jan; 6(1):62-73. PubMed ID: 31952783
[TBL] [Abstract][Full Text] [Related]
12. The Rho GTPase RhoE is a p53-regulated candidate tumor suppressor in cancer cells.
Zhu Y; Zhou J; Xia H; Chen X; Qiu M; Huang J; Liu S; Tang Q; Lang N; Liu Z; Liu M; Zheng Y; Bi F
Int J Oncol; 2014 Mar; 44(3):896-904. PubMed ID: 24399089
[TBL] [Abstract][Full Text] [Related]
13. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
14. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
16. Rad is a p53 direct transcriptional target that inhibits cell migration and is frequently silenced in lung carcinoma cells.
Hsiao BY; Chen CC; Hsieh PC; Chang TK; Yeh YC; Wu YC; Hsu HS; Wang FF; Chou TY
J Mol Med (Berl); 2011 May; 89(5):481-92. PubMed ID: 21221513
[TBL] [Abstract][Full Text] [Related]
17. Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer.
Ali A; Bhatti MZ; Shah AS; Duong HQ; Alkreathy HM; Mohammad SF; Khan RA; Ahmad A
J Biol Chem; 2015 Aug; 290(35):21336-51. PubMed ID: 25911104
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14.
Du Y; Liu Z; You L; Hou P; Ren X; Jiao T; Zhao W; Li Z; Shu H; Liu C; Zhao Y
Cancer Res; 2017 May; 77(10):2661-2673. PubMed ID: 28280038
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53 drives invasion by promoting integrin recycling.
Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer.
Shakya R; Tarulli GA; Sheng L; Lokman NA; Ricciardelli C; Pishas KI; Selinger CI; Kohonen-Corish MRJ; Cooper WA; Turner AG; Neilsen PM; Callen DF
Oncogene; 2017 Aug; 36(31):4469-4480. PubMed ID: 28368395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
